Format

Send to

Choose Destination
J Hematother Stem Cell Res. 2002 Jun;11(3):469-81.

Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses.

Author information

1
Division of Hematology, Department of Internal Medicine, Gade Institute, Department of Anatomy and Cell Biology, Haukeland University Hospital, University of Bergen, Bergen, Norway.

Abstract

During the last decade, several large clinical studies have demonstrated that analysis of chromosomal abnormalities is an essential basis for therapeutic decisions in patients with acute myelogenous leukemia (AML), and cytogenetic studies should now be regarded as mandatory both for routine treatment and as a part of clinical investigations in AML. However, new techniques for detailed genetic characterization and analysis of gene expression as well as protein modulation will become important in the further classification of AML subsets and the development of risk-adapted therapeutic strategies. In this context, we emphasize the importance of population-based clinical studies as a basis for future therapeutic guidelines. Such studies will then require the inclusion of patients at small clinical centers without specialized hematological research laboratories. To document a high and uniform quality of the laboratory investigations, it will be necessary to collect material for later analysis in selected laboratories. In this article, we describe current methods for collection of biological samples that can be used for later preparation of DNA, RNA, and proteins. With the use of gradient-separated AML cells, it should be possible to establish the necessary techniques for collection and handling of biological samples even at smaller centers, and complete collections from all included patients should then be possible even in population-based clinical studies.

PMID:
12183832
DOI:
10.1089/15258160260090933
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center